Diasorin SpA (CHIX:DIAM) 1-Year Sharpe Ratio: -0.83 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIAM Diasorin SpA CHIX:DIAM
78 GF Score
Price €69.54
GF Value €90.24
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA 1-Year Sharpe Ratio?

Diasorin SpA CHIX:DIAM -1.71% 78 1-Year Sharpe Ratio is -0.83 as of Jul. 14, 2026. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €90.24 (Modestly Undervalued). The stock has 6 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-14), Diasorin SpA's 1-Year Sharpe Ratio is -0.83.

Diasorin SpA  (CHIX:DIAm) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Diasorin SpA 1-Year Sharpe Ratio Related Terms

CHIX:DIAM vs TMO, DHR, IDXX: 1-Year Sharpe Ratio Comparison

For the Diagnostics & Research subindustry, Diasorin SpA's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA 1-Year Sharpe Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's 1-Year Sharpe Ratio falls into.


CHIX:DIAM
78GF Score
Diasorin SpA CHIX:DIAM
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.83 mean?
Diasorin SpA (CHIX:DIAM) has a 1-Year Sharpe Ratio of -0.83 as of Jul. 14, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Diasorin SpA and its competitors.
Is Diasorin SpA's 1-Year Sharpe Ratio too high?
Diasorin SpA's current 1-Year Sharpe Ratio is -0.83. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 1-Year Sharpe Ratio compare to TMO and DHR?
Diasorin SpA's 1-Year Sharpe Ratio of -0.83 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Diagnostics & Research company?
A good 1-Year Sharpe Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Diasorin SpA and its competitors. Diasorin SpA's current 1-Year Sharpe Ratio is -0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.24, compared to a current price of €69.54 — trading 22.9% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.83. Diasorin SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current 1-Year Sharpe Ratio is -0.83 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for CHIX:DIAM:

  • 1-Year Sharpe Ratio: -0.83
  • GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score

Get the complete analysis for CHIX:DIAM

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.54
Price
€90.24
GF Value